RealClearHealth

The Future of Public Health 2026

Trust, Cost, and Risk in the Next Decade of Public Health

Presented by the Journal of the Academy of Public Health, in cooperation with RealClearHealth, the inaugural Future of Public Health conference convenes senior policymakers, industry leaders, clinicians, and researchers for a focused day on the forces reshaping American healthcare: trust, cost, and risk. Six panel discussions will bridge the divide between academic public health and the economics of health policy, offering a clear-eyed picture of where America's health is now—and where it should be heading.

DateWednesday, September 9, 2026
LocationNed's Club · Washington, D.C.
FormatOne Day · Six Conversations · Invite Only
§ 01

Program

Six sessions across one day, including two fireside chats and a luncheon keynote. Panelists added as they confirm.

At a GlanceWed · Sep 9, 2026 · 8:30a–4:30p
Morning8:30a – 12:00p
8:309:00WelcomeArrival & Continental Breakfast
9:009:20RemarksIntroductory Remarks
9:3010:15Session IPrescription Drugs
11:0011:15BreakCoffee
11:1512:00Session IIIHospitals & Insurance
Afternoon12:00p – 4:30p
12:001:00KeynoteLuncheon Keynote Address
2:002:45Session VPrior Authorization
2:453:00BreakCoffee
Session01
9:30 — 10:15

Prescription Drugs

Overview

This year's program opens with a hard-edged look at prescription drug policy, where debates over intellectual property, MFN pricing, PBMs, and the future of generics and biosimilars are converging into one of the most consequential policy fights heading into the midterms. Featuring leaders across government, industry, and patient advocacy. The discussion reflects a system under pressure to reconcile innovation with affordability, and rhetoric with results.

Session02
10:15 — 11:00

Frontiers of Biosecurity: A Fireside Chat with Dr. Robert Redfield

Overview

An intimate fireside chat with Dr. Robert Redfield, virologist and former CDC Director, in conversation with host and moderator Dr. Laura Kahn—a physician, policy researcher, and co-founder of the One Health Initiative, and Biosafety Now! board member who spent nearly two decades as a research scholar at Princeton University. Over a career spanning four decades on the front lines of infectious disease, Dr. Redfield has never shied away from difficult truths. Drawing on themes from his latest book, Redfield's Warning, he'll share reflections on a life spent studying viruses, the lessons of past pandemics, and what he believes the future may hold for public health and biosecurity in a fraught and uncertain time.

Session03
11:15 — 12:00

Hospitals & Insurance

Overview

The morning continues with a broader examination of healthcare costs and system design, from 340B and ACA subsidy expansion to hospital consolidation, physician shortages, and the growing disconnect between spending and outcomes. A cross-sector panel will explore how policy choices across both parties have reshaped incentives throughout the system—and what it would take to restore transparency and competition.

Session04
1:15 — 2:00

Gain-of-Function Research: A Fireside Chat with Dr. Simon Wain-Hobson

Overview

A fireside chat with Dr. Simon Wain-Hobson. Andrew Noymer (UC Irvine and JAPH EiC) in conversation with eminent virologist Simon Wain-Hobson (Institut Pasteur, retired), author of the "On Reading" blog. This discussion will touch upon the benefits and risks of gain-of-function virology research, and how we should approach high-containment BSL research, both as it relates to possible explanations of the emergence of SARS-CoV-2, and more generally.

Session05
2:00 — 2:45

Prior Authorization

Overview

Prior authorization deserves a central place on any serious health conference agenda because it sits at the messy intersection of cost control, clinical autonomy, and patient access—and too often fails on all three. What began as a utilization management tool has metastasized into a bureaucratic choke point that delays care, burns out clinicians, and leaves patients stuck navigating denials and appeals for treatments their doctors already know are appropriate. The policy debate isn't whether some guardrails are necessary in a high-cost system, but whether the current model—defined by opaque criteria, inconsistent standards across payers, and sluggish response times—actually improves outcomes or just shifts costs onto providers and patients in the form of time, paperwork, and missed care.

Session06
3:00 — 4:30

Vaccines in the 21st Century: Where Do We Go from Here?

Overview

In a landmark and controversial vote last December, the Advisory Committee on Immunization Practices (ACIP) recommended the removal of the Hepatitis B vaccine from the American childhood vaccination schedule. This was soon followed by an historic overhaul of the entire schedule by the CDC, striking 7 vaccines from the list of pediatric recommendations.

This panel convenes experts from both sides of this widening divide—ACIP members past and present, pediatric infectious disease specialists, industry veterans, government officials, and clinicians—to assess the evidence base behind these decisions, America's vaccination practices relative to peer nations, and the future outlook for vaccine policy and science in the country.

§ 02

Speakers

Keynote, panelists, and moderators for the day. Select View Full Bio for the complete biography.

KeynoteLuncheon keynote address01
Dr. Sandro Galea

Dr. Sandro Galea

Margaret C. Ryan Dean, School of Public Health

Washington University in St. Louis

Dr Galea is a population health scientist, physician, and author. He is the Margaret C Ryan Dean, the Eugene S and Constance Kahn Distinguished Professor in Public Health at the Andrew M and Jane M Bursky School of Public Health, and Vice Provost of Interdisciplinary Initiatives at Washington University in St. Louis.

PanelistsAcross six sessions14
RR

Dr. Robert Redfield

Former Director, U.S. Centers for Disease Control and Prevention

GBMC Health Partners; University of Maryland School of Medicine

Robert R. Redfield, MD, is a board-certified Infectious Disease and Internal Medicine physician at GBMC Health Partners Primary Care—Texas Station. Dr. Redfield earned his medical degree at Georgetown University School of Medicine and completed his medical residency at Walter Reed Army Medical Center. After founding the Department of Retroviral Research within the U.S. Military Research Program, Dr. Redfield co-founded the University of Maryland's Institute of Human Virology. Additionally, he served as the Chief of Infectious Diseases and Vice Chair at the University of Maryland School of Medicine. In 2018, Dr. Redfield became director of the Centers for Disease Control and Prevention (CDC) and led the organization's response to COVID-19. Dr. Redfield has also served as a Senior Adviser for Public Health to Governor Larry Hogan, with a focus on coronavirus variants, COVID-19 vaccines, and public health.

SW

Dr. Simon Wain-Hobson

Emeritus Professor

Pasteur Institute, Paris

Simon Wain-Hobson is an emeritus professor at the Institut Pasteur, Paris, from which he retired in 2021. He and his colleagues were the first to sequence the genome of HIV, and Wain-Hobson has published more than 230 papers on virology and cancer. Wain-Hobson is the co-founder of two biotech companies working to develop countermeasures against cancer.

RADM Scott Giberson

RADM Scott Giberson

Former Deputy U.S. Surgeon General

CEO, AMI Expeditionary Healthcare

RADM (Ret) Scott F. Giberson is a retired two-star Admiral and currently the CEO of AMI Expeditionary Healthcare, a global healthcare solutions company. During his 26 years of service, he held many executive and senior leadership positions in the Corps such as the Senior Advisor to the Office of Surgeon General, Director of Commissioned Corps Headquarters, Chief Pharmacy Officer (CPO) and a Senior Public Health Advisor for the Department of Defense, at Pacific Command. He also served as the Corps' overall Commander of the Ebola Response in West Africa.

DF

Dr. Dorothy Fink

Director, Office on Women's Health

U.S. Department of Health & Human Services

Dr. Dorothy Fink is Deputy Assistant Secretary for Women's Health and Director of the Office on Women's Health in the Office of the Assistant Secretary for Health (OASH) at the U.S. Department of Health and Human Services.

GA

Dr. Gary Andres

Assistant Secretary for Legislation

U.S. Department of Health & Human Services

Gary Andres is currently the Assistant Secretary for Legislation in the Department of Health and Human Services. Mr. Andres served as the Republican Staff Director for the House Ways and Means Committee from 2018 to 2022 and for the House Energy and Commerce Committee from 2011 to 2017. He also worked in the White House Office of Legislative Affairs for Presidents George H.W. Bush and George W. Bush. Previously, he worked at the Biotechnology Innovation Organization and Dutko Worldwide. Mr. Andres received his undergraduate degree in Social Science from Wheaton College. He also holds a Master's in Political Science and a Ph.D. in Public Policy Analysis from the University of Illinois-Chicago.

NK

Dr. Nathan Kuppermann

Executive Vice President & Chief Academic Officer

Children's National Hospital

Nathan Kuppermann, MD, MPH, is executive vice president, chief academic officer of Children's National and director of the Children's National Research Institute. He also serves as chair of the Department of Pediatrics and associate dean of Pediatric Academic Affairs at the George Washington University School of Medicine and Health Sciences. He is also a member of the Center for Health Outcomes Research & Delivery Science, and he holds the Fight for Children Professorship in the Department of Pediatrics at the George Washington University School of Medicine and Health Sciences.

Joel White

Joel White

President

Council for Affordable Health Coverage

Joel White is President of the Council for Affordable Health Coverage, where he leads a seasoned government affairs team and manages a coalition of more than 30 organizations representing patients, manufacturers, providers, employers, and other health care stakeholders committed to lowering costs.

Dr. Matthew Zahn

Dr. Matthew Zahn

Pediatric Infectious Disease Clinician

Rady Children's Health

Dr. Zahn has worked in local public health for 20 years, including overseeing immunization and communicable disease control programs for a diverse county of 3.2 million residents. In that capacity, he led the public health response to community outbreaks of vaccine-preventable diseases. He has been active at the local, state, and national levels in advocating for support of the role of local public health in protecting communities against infectious diseases. He currently works as a pediatric infectious disease clinician who sees patients at Rady Children's Health in Orange County, California.

JM

Dr. Joseph Marine

Professor of Medicine

Johns Hopkins School of Medicine

Joseph Marine, MD, MBA, FACC, FHRS, is a clinical cardiac electrophysiologist who practices primarily at the Johns Hopkins Hospital in Baltimore, Maryland. He is a Professor of Medicine at the Johns Hopkins University School of Medicine and holds appointments as Vice-Director of Operations for the Division of Cardiology and Section Chief of Cardiology for Johns Hopkins Community Physicians. He trained at UC San Francisco Medical School, Brigham and Women's Hospital/Harvard Medical School, Boston University Medical Center, and Beth Israel Deaconess Medical Center.

PP

Peter Pitts

President & Co-Founder

Center for Medicine in the Public Interest

Peter Pitts is president and co-founder of the Center for Medicine in the Public Interest. He also serves as a visiting professor at the University of Paris School of Medicine. Pitts is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration where he served as senior communications and policy adviser to the Commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency's obesity working group and counterfeit drug taskforce. He is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines.

AU

Dr. Adam Urato

Maternal-Fetal Medicine Clinician

MetroWest Medical Center

Dr. Urato is an Obstetrician and Gynecologist specializing in Maternal-Fetal Medicine. Dr. Urato has held academic appointments at Harvard Medical School, the University of South Florida, and Tufts University School of Medicine. His clinical roles have included Maternal-Fetal Medicine attending positions at MetroWest Medical Center, Beth Israel Deaconess Medical Center, Boston Medical Center/St. Elizabeth's, and Tufts Medical Center. Dr. Urato received his B.A. from Harvard College and his M.D. from Harvard Medical School. He has also published extensively in peer-reviewed journals and participated in FDA advisory panels.

JH

Jackson Hammond

Senior Policy Analyst

Paragon Health Institute

Jackson Hammond is a Senior Policy Analyst at Paragon Health Institute. He has been active in the federal and state health policy space since 2017.

Julienne Verdi

Julienne Verdi

Executive Director

Alliance for Headache Disorders Advocacy

Julienne Verdi is the Executive Director of the Alliance for Headache Disorders Advocacy and The Headache Alliance. She leads national efforts to advance policy, education, and patient advocacy for people living with migraine and headache disorders.

JR

Juliana M. Reed

Executive Director

Biosimilars Forum

Juliana M. Reed is an accomplished healthcare executive having spent the last 40 years working in both the US healthcare system as both a clinician and hospital administrator, as well the global pharmaceutical and medical device industries in corporate and government affairs executive roles. Ms. Reed has over 20 years' global experience in pharmaceutical and medical device regulatory pathways, reimbursement and government policy. She has direct experience in the US, Canada, LATAM, and throughout APAC and Europe.

ModeratorsChairing the day's sessions04
Dr. Laura Kahn

Dr. Laura Kahn

Physician, Policy Researcher & Author

Formerly Princeton University

Dr. Laura H. Kahn is a physician, policy researcher, educator, and author. For almost 20 years, she was a research scholar in the Program on Science and Global Security at Princeton's School of Public and International Affairs, Princeton University. Her education and training encompass nursing, medicine, public health, and public policy.

Sue Peschin

Sue Peschin

President & CEO

Alliance for Aging Research

Sue Peschin, MHS, serves as President and CEO of the Alliance for Aging Research, the leading nonprofit organization dedicated to changing the narrative to achieve healthy aging and equitable access to care. Since 2012, Ms. Peschin has led the Alliance team on efforts to increase federal investment in aging research; develop Talk NERDY (Nurturing Engagement in Research and Development with You), a research engagement network; and advocate for equitable Medicare affordability and access. Sue is an accomplished speaker and thought leader, whose writing has been published in peer-reviewed journals and top-tier newspapers. Ms. Peschin serves on the Boards of Directors for the Association of Black Cardiologists; the National Health Council; and the U.S. Pharmacopeia (USP). She also serves as a member of the Science Advisory Board for the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation and on the UMD Claude D. Pepper Older Americans Independence Center Community Advisory Board. Previously, Sue served in senior roles at the Alzheimer's Foundation of America, Consumer Federation of America, Hadassah, and the Violence Policy Center.

Dr. Andrew Noymer

Dr. Andrew Noymer

Professor; Editor-in-Chief, Journal of the Academy of Public Health

University of California, Irvine

Andrew Noymer, MSc, PhD, Editor-in-Chief, is an associate professor of population health and disease prevention at the University of California Irvine, United States. From an epidemiological, demographic and social perspective, he has done research on influenza pandemics. Dr. Noymer is one of the world experts on infectious disease mortality, and he serves on the UN/WHO Technical Advisory Group on Covid-19 mortality estimation. Dr. Noymer is also the Editor-in-Chief of the Journal of the Academy of Public Health. For his work educating the public about epidemiology during the covid pandemic, Dr Noymer was listed in the Orange County Register "most influential people" in 2020 and 2022.

JR

Jerry Rogers

Editor

RealClearHealth

§ 03

About the Conference

Presented by

The Journal of the Academy of Public Health, in cooperation with RealClearHealth

Health policy is at the front-burner in Washington — it is central to questions of economic security, innovation, and public trust in institutions. The inaugural Future of Public Health conference brings together senior policymakers, industry leaders, clinicians, and researchers for a focused day on the forces reshaping American healthcare: access, affordability, innovation, and trust.

This year's program opens with a hard-edged look at prescription drug policy, where debates over intellectual property, MFN pricing, PBMs, and the future of generics and biosimilars are converging into one of the most consequential policy fights heading into the midterms. The morning continues with a broader examination of healthcare costs and system design, from 340B and ACA subsidy expansion to hospital consolidation, physician shortages, and the growing disconnect between spending and outcomes.

After a plenary keynote, the afternoon turns to public health and system integrity, including biosafety governance, prior authorization reform, and a high-profile vaccines debate featuring leading voices from across the scientific and policy spectrum. These sessions are designed not for consensus, but for clarity — surfacing the real points of disagreement that will define the next phase of U.S. health policy.

The conference will close with senior voices from government and public health, followed by networking with stakeholders across the health ecosystem. As Washington moves deeper into an election cycle where healthcare will again be central, the conference offers a rare forum where competing ideas are tested directly, not filtered through partisan shorthand.

Contact

editor@rcjpublichealth.org
Press & Media

Credentialed press should contact the Editorial Office at editor@rcjpublichealth.org by August 15 to request access to selected sessions and on-site interviews.

One day. Six conversations. By invitation.

The inaugural Future of Public Health conference is an invite-only event with seats reserved for public health and health policy professionals. Invitations will come via email from Jerry Rogers (RealClearHealth), Andrew Noymer (Journal of the Academy of Public Health), or other individuals affiliated with RealClear. RSVP as soon as possible to secure your seat, as space is limited.